Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best High Volume Penny Stocks to Buy. On December 17, Priyanka Grover from J.P. Morgan upgraded Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ...

Access detailed historical stock prices, including daily closing prices, for RXRX. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...

Amber Implants, a Netherlands medtech developing next-generation implants for spinal injuries, named Vincent Gardès as CEO.

Gain-of-function research (GOFR) refers to the serial passaging of microorganisms to increase their transmissibility, virulence, immunogenicity, and host tropism by applying selective pressure to a ...

For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...

Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of ...